TECHHIGH SIGNALFINANCIAL10-K

TECH's profitability deteriorated substantially with net income and operating income both declining meaningfully while SG&A expenses increased over 25%.

The company appears to be facing significant operational challenges as profitability declined sharply despite what seems to be an established business model in protein sciences and diagnostics. The simultaneous reduction in capital expenditures suggests management may be pulling back on growth investments while struggling with cost control, as evidenced by the substantial increase in SG&A expenses.

Comparing 2025-08-22 vs 2024-08-22View on EDGAR →
FINANCIAL ANALYSIS

TECH's financial performance weakened considerably with both net income and operating income declining substantially year-over-year. SG&A expenses grew over 25% to $588.5M, indicating potential cost control issues or significant investments that have not yet translated to profitability. The company also meaningfully reduced capital expenditures from $62.9M to $31.0M, suggesting either improved efficiency or a pullback in growth investments during this challenging period.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-56.3%
$168.1M→$73.4M

Net income declined 56.3% — review whether driven by operations, interest costs, or non-recurring items.

Capital Expenditure
Cash Flow
-50.7%
$62.9M→$31.0M

Capex reduced 50.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Income
P&L
-50.5%
$206.7M→$102.3M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

SG&A Expense
P&L
+26.2%
$466.4M→$588.5M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Accounts Receivable
Balance Sheet
-14.3%
$241.4M→$206.9M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Current Liabilities
Balance Sheet
+10.3%
$159.4M→$175.8M

Current liabilities rose 10.3% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2025-08-22
PRIOR — 2024-08-22
ADDED
As of August 18, 2025, 155,549,587 shares of the Company s Common Stock ($0.01 par value) were outstanding.
Our broad product portfolio and application expertise enables scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases.
We manage the business in two operating segments our Protein Sciences segment and our Diagnostics and Spatial Biology segment.
Today, our product lines include hundreds of thousands of diverse products, most of which we manufacture ourselves in multiple locations in North America, as well as locations in the U.K., Canada, Switzerland and China.
Recent examples include the investment in Spear Bio at the beginning of fiscal 2025 and the acquisition of Lunaphore SA ( Lunaphore ) at the beginning of fiscal 2024.
Protein Sciences Segment Customers and Distribution Methods Our customers for this segment include researchers in academia and industry (chiefly pharmaceutical and biotech companies as well as contract research organizations).
This segment also sells to diagnostic/companion diagnostic and therapeutic customers, including those engaged in the development of cell- and gene-based therapies.
The Asuragen-branded products are sold primarily to laboratories for use in lab-developed tests or in kit form as regulated diagnostic tests.
As a party to these contracts, Bio-Techne does have to comply with certain regulations that apply to companies doing business with governments.
We strive to create an employee experience that allows each to achieve their full potential.
REMOVED
As of August 16, 2024, 158,600,408 shares of the Company s Common Stock ($0.01 par value) were outstanding.
Investment in our securities involves risk and uncertainty and you should carefully consider all information in this Annual Report on Form 10-K prior to making an investment decision regarding our securities.
Below is a summary of material risks and uncertainties we face, which are discussed more fully in Item 1A.
Our growth depends in part on the timely development and commercialization of new and enhanced products and services that meet our customers needs.
A significant disruption in, or breach of security of, our information technology systems or data, or violation of data privacy laws, could result in damage to our reputation, data integrity, and/or subject us to costs, fines, or lawsuits under data privacy or other laws or contractual requirements.
If we suffer a loss to our supply chains, distribution systems or information technology systems due to catastrophe or other events, our operations could be seriously harmed.
The Company relies heavily on internal manufacturing and related operations to produce, package and distribute its products which, if disrupted, could materially impair our business operations.
Because we rely heavily on third-party package-delivery services, a significant disruption in these services or significant increases in prices may disrupt our ability to ship products, increase our costs and lower our profitability.
With our broad product portfolio and application expertise, we sell integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases.
We manage the business in two operating segments our Protein Sciences segment and our Diagnostics and Genomics segment.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →